Gujarat Themis Biosyn Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended 31st March, 2026. The pharmaceutical company filed the mandatory certificate with both BSE and NSE, demonstrating adherence to regulatory requirements for dematerialisation procedures.

Regulatory Compliance Details

The certificate was submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to confirm proper handling of securities received for dematerialisation during each quarter.

Certificate Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, issued the confirmation certificate on April 3, 2026. The registrar confirmed that all securities received from depository participants for dematerialisation during Q4FY26 were properly processed within prescribed timelines.

The certificate specifically confirms that:

• Securities received for dematerialisation were accepted or rejected appropriately
• Security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners
• All procedures were completed within regulatory timelines

Stock Exchange Filing

Company Secretary and Compliance Officer Vineet Gawankar submitted the certificate to both major stock exchanges on 8th April, 2026. The filing ensures transparency and regulatory compliance for shareholders and market participants.

This quarterly submission represents Gujarat Themis Biosyn Limited's ongoing commitment to maintaining regulatory compliance and transparent corporate governance practices in accordance with SEBI guidelines.

Gujarat Themis Biosyn Limited has published its postal ballot notice in newspapers as required under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The pharmaceutical company, engaged in manufacturing fermentation-based Active Pharmaceutical Ingredients, published the notice in Western Times (English) and Western Times (Gujarati) editions on Thursday, 19th March, 2026.

Regulatory Compliance and Publication Details

The company has fulfilled its regulatory obligations by publishing the postal ballot notice in accordance with SEBI Listing Regulations. Company Secretary and Compliance Officer Vineet Gawankar confirmed the publication through an official communication to stock exchanges BSE Limited and National Stock Exchange of India Limited.

Key Resolutions for Shareholder Approval

The postal ballot encompasses two critical items requiring shareholder consideration through remote e-voting. The first resolution involves the re-appointment of Mrs. Kirandeept Madan as Non-Executive Woman Independent Director, while the second addresses material related party transactions with Themis Medicare Limited.

Director Re-appointment Details

The company proposes re-appointing Mrs. Kirandeept Madan (DIN: 00686547) as Non-Executive Woman Independent Director for a second term of five consecutive years. Her current term, which began on May 1, 2021, will expire on April 30, 2026. The proposed re-appointment will be effective from May 1, 2026 to April 30, 2031.

Mrs. Madan brings extensive experience as a Physiotherapist and Sociologist, with over 25 years of involvement in social work. She founded Sanskar India Foundation, a non-profit organization working on environment and social causes, and has been leading the organization as Director. Her flagship program 'Sanskar' operates successfully in over 150 schools across three languages.

Material Related Party Transactions

The second resolution seeks approval for material related party transactions with Themis Medicare Limited (TML) for an aggregate value of Rs. 50 Crores during Financial Year 2026-27. TML is a Promoter Group Company holding 23.19% equity share capital of Gujarat Themis Biosyn Limited.

Transaction Background and Rationale

The proposed transactions involve sale of fermentation-based Active Pharmaceutical Ingredients, intermediates, and other operational activities. These transactions are conducted in the ordinary course of business and on an arm's length basis, with pricing benchmarked to prevailing market prices and landed cost of products in India.

The transactions ensure stable demand and offtake of fermentation-based APIs manufactured by the company, supporting operational continuity and production efficiency. The Audit Committee has reviewed and approved these transactions after confirming they comply with the company's Related Party Transactions Policy and applicable laws.

E-Voting Process and Timeline

The company has engaged Central Depository Services (India) Limited (CDSL) to provide remote e-voting facility. The voting process will be conducted exclusively through electronic means, with no physical postal ballot forms being distributed.

Members whose names appear in the Register of Members or list of Beneficial Owners as on the cut-off date and whose email addresses are registered with the company, Registrar and Transfer Agent, or Depositories will be eligible to participate in the e-voting process.

Corporate Governance and Compliance

The postal ballot notice demonstrates the company's commitment to corporate governance and regulatory compliance. The resolutions address key aspects of board composition and business operations, ensuring transparency in decision-making processes.

The re-appointment of Mrs. Madan as Independent Director aligns with regulatory requirements under the Companies Act, 2013 and SEBI Listing Regulations. Her performance evaluation by the Board of Directors, in consultation with the Nomination & Remuneration Committee, has been positive, highlighting her valuable contributions to governance, social impact, and stakeholder engagement.

For the related party transactions, the company has provided comprehensive disclosures as per SEBI Master Circular requirements, including detailed financial information about Themis Medicare Limited and justification for the proposed transactions. The approval process ensures arm's length pricing and adherence to regulatory frameworks governing related party transactions.